Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.

H Wedemeyer, X Forns, Christophe HEZODE, SS Lee, A Scalori, A Voulgari, S Le Pogam, I Najera, JA Thommes,

PLoS One. 11/01/2016;11(1) : e0145409 10.1371/journal.pone.0145409.

Why I do not treat patients for mild disease.

Christophe HEZODE,

Liver Int 01/01/2016;36 suppl 1 : 13-20 10.1111/liv.13019.

Ideal oral combinations to eradicate HCV: The role of ribavirin.

Christophe HEZODE, JP Bronowicki,

J Hepatol. 01/01/2016;64(1) : 215-225 10.1016/j.jhep.2015.09.009. 26/09/2015

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

JJ Feld, IM Jacobson, Christophe HEZODE, T Asselah, PJ Ruane, N Gruener, A Abergel, A Mangia, CL Lai, HL Chan, F Mazzotta, C Moreno, E Yoshida, SD Shafran, WJ Towner, TT Tran, J McNally, A Osinusi, E Svarovskaia, Y Zhu, DM Brainard, JG McHutchison, K Agarwal, S Zeuzem,

N Engl J Med. 31/12/2015;373(27) : 2599-2607 10.1056/NEJMoa1512610. 16/11/2015

Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.

F About, T Oudot-Mellakh, J Niay, P Rabiega, V Pedergnana, D Duffy, P Sultanik, C Cagnot, F Carrat, P Marcellin, F Zoulim, D Larrey, Christophe HEZODE, H Fontaine, JP Bronowicki, S Pol, ML Albert, I Theodorou, A Cobat, L Abel,

PLoS One. 15/12/2015;10(12) : e0145105 10.1371/journal.pone.0145105.

The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.

J Boursier, A Ducancelle, J Vergniol, P Veillon, V Moal, C Dufour, JP Bronowicki, D Larrey, Christophe HEZODE, F Zoulim, H Fontaine, V Canva, T Poynard, S Allam, V De Ledinghen,

J Viral Hepat. 01/12/2015;22(12) : 1002-1010 10.1111/jvh.12433. 27/07/2015

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.

Jean-Michel PAWLOTSKY, R Flisiak, SK Sarin, J Rasenack, T Piratvisuth, WL Chuang, CY Peng, GR Foster, S Shah, H Wedemeyer, Christophe HEZODE, W Zhang, KA Wong, B Li, C Avila, NV Naoumov,

Hepatology. 01/10/2015;62(4) : 1013-1023 10.1002/hep.27960. 10/08/2015

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.

E Lawitz, M Makara, US Akarca, PJ Thuluvath, LL Preotescu, P Varunok, RM Morillas, C Hall, N Mobashery, R Redman, T Pilot-Matias, RA Vilchez, Christophe HEZODE,

Gastroenterology 01/10/2015;149(4) : 971-980.e1 10.1053/j.gastro.2015.07.001. 11/07/2015

Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.

F Bailly, V Virlogeux, C Dufour, P Pradat, Christophe HEZODE, D Larrey, L Alric, D Samuel, M Bourliere, S Metivier, JP Zarski, H Fontaine, V Loustaud-Ratti, L Serfaty, JP Bronowicki, F Carrat, F Zoulim,

Clin Res Hepatol Gastroenterol. 01/09/2015;39(4) : 443-450 10.1016/j.clinre.2014.12.007 27/01/2015

Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4).

Christophe HEZODE, L Alric, A Brown, T Hassanein, M Rizzetto, M Buti, M Bourliere, D Thabut, E Molina, V Rustgi, D Samuel, F McPhee, Z Liu, PD Yin, E Hughes, M Treitel, COMMAND-4 study team

Anticir Ther 27/08/2015;21(3) : 195-205 10.3851/IMP2985.